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Abstract
Background: In Pakistan,the estimated prevalence of chronic obstructive pulmonary disease
(COPD) and asthma are 2.1% and 4.3% respectively, and existing care is grossly lacking both in
coverage and quality. An integrated approach is recommended for delivering COPD and asthma
care at public health facilities.
Aim: To understand how an integrated care package was experienced by care providers and
patients, and to inform modifications prior to scaling up.
Design & setting: The mixed-methods study was conducted as part of cluster randomised trials on
integrated COPD and asthma care at 30 public health facilities.
Method: The care practices were assessed by analysing the clinical records of n = 451 asthma and
n = 313 COPD patients. Semi-structured interviews with service providers and patients were used
to understand their care experiences. A framework approach was applied to analyse and interpret
qualitative data.
Results: Utilisation of public health facilities for chronic lung conditions was low, mainly because of
the non-availability of inhalers. When diagnosed, around two-thirds (69%) of male and more than
half (55%) of female patients had severe airway obstruction. The practice of prescribing inhalers
differed between intervention and control arms. Patient non-adherence to follow-up visits remained
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a major treatment challenge (though attrition was lower and slower in the intervention arm).
Around half of the male responders who smoked at baseline reported having quit smoking.
Conclusion: The integrated care of chronic lung conditions at public health facilities is feasible and
leads to improved diagnosis and treatment in a low-income country setting. The authors
recommend scaling of the intervention with continued implementation research, especially on
improving patient adherence to treatment.
How this fits in
Integrated care of chronic lung conditions is a known priority of non-communicable disease pro-
grammes, and evidence is needed for an informed programme scaling decision. This process evalua-
tion study was conducted, as part of two intervention trials, to help the programme understand and
refine the delivery and support of COPD and asthma care in public health facility settings.
Introduction
The global prevalences of COPD and asthma were estimated at 251 million and 235 million respec-
tively, causing 3.17 million and 383 000 annual deaths.1,2 Pakistan, a lower-middle income country
with a population of around 200 million, is facing a high burden of chronic respiratory diseases,
including COPD and asthma. The age-standardised mortality rate due to chronic respiratory diseases
is estimated to be 138.2 per 100 000 in males and 41.3 per 100 000 among females in Pakistan. A
multi-country survey (BREATHE) reported a 2.1% prevalence of COPD among Pakistani adults aged
>40 years. It is expected that the COPD morbidity and mortality rates will increase in concurrence
with the increasing trend of smoking, one of its major risk factors. According to a national health sur-
vey, prevalence of smoking was 28.6% among males and 3.4% among females.3 Clinical asthma
prevalence has been estimated to be 4.3%,4 and as high as 10.7% among children aged 13–14
years.5 High chronic respiratory disease prevalence poses a challenge to economic development,
and to the quality of life of the population. Integration of clinical management at primary health care
(PHC) level is the recommended approach to achieve universal coverage of non-communicable dis-
ease care.6
In Pakistan, PHC is delivered through a network of PHC facilities (such as basic health units at
union council, and rural health centres at cluster levels)7 and sub-district level hospitals. The District
Health Office is responsible for managing the provision of public-funded care at primary and second-
ary level facilities. These publicly-funded health centres and hospitals are staffed with doctors and
allied staff, and are equipped with basic laboratory facilities such as blood and urine testing, and
microscopy. The lack of programme guidelines and tools for diagnosis, treatment, and education of
patients is known to result in a widely varied and poor quality care provision, as well as inadequate
patient response to the care requirements.8
To address the practice variation and care quality challenges, a set of contextualised products
were developed for delivering integrated chronic lung care at primary and secondary level facilities.
The Provincial Non-Communicable Disease Programme and its partners developed the contextual-
ised products by adapting international best practice guidelines.9–11 The care delivery products
mainly included: a case management desk-guide; training for doctors and allied staff; and an educa-
tion tool for patients (Box 1).
During the intervention development (through the Technical Working Group of stakeholders) cer-
tain assumptions were made about the circumstances and behaviour of health facility staff and
patients with chronic respiratory disease. A process evaluation was conducted alongside the two tri-
als to a) allow better understanding of the COPD and asthma care delivery experiences, for exam-
ple, feasibility and acceptability for both facility staff and patients; b) distinguish between the care
practice deviation because of a faulty design or implementation failure;12 and c) inform future scaling
on the intervention through public programme resources.
The main aims were therefore to explore how the intended intervention components were imple-
mented and experienced by the care providers and patients; and to identify how the intervention
components could be further strengthened for delivering quality chronic respiratory disease care at
public health facilities.
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Method
The process evaluation employed a sequential mixed-methods design. The quantitative data from
patient clinical records were used to assess the fidelity to the care protocols. The qualitative inter-
views of service providers and patients were conducted to understand participants’ experiences and
reasons for deviations from the care protocols. The research team, in consultation with programme
staff, identified three sets of task categories to study the intervention. These pre-defined care task
categories were: identification and diagnosis of cases; treatment and prevention of chronic lung con-
ditions; and patient follow-up and referral care. Then for each task category, a set of quantitative
and qualitative indicators were selected. Box 2 summarises the key selected indicators for the three
task categories.
The quality of clinical records (the source of quantitative data) was ensured by providing addi-
tional training to providers, monitoring the data completeness, and querying any data that appeared
implausible. The patient records, collected from July 2015–September 2016, were entered into SPSS
(version 17.0). Data were single-entered and the quality was assured by data entry checking at regu-
lar intervals to minimise error rates.13 The frequency distribution of the data was analysed and cross-
tabulated it by sex, and intervention and control.
Facility and participant selection
The enhanced care (with these products) was implemented and evaluated through a cluster rando-
mised controlled trial at 30 public-funded facilities in three selected districts of Sargodha, Kasur, and
Mandi Bahauddin. These facilities were randomised to the intervention and control arm on a 1:1
basis using a lottery method. All patients newly diagnosed with COPD or asthma, aged 18 years,
and currently living (and expected to continue living for the next 12 months) in the catchment area
of the respective health facility were eligible for the study. Patients fulfilling the inclusion criteria but
refusing to participate were excluded. A total of 451 asthma and 313 COPD patients were diag-
nosed, registered, treated, and followed up for 6 months by doctors to measure and compare the
treatment outcomes (for asthma, control achieved as per Global Initiative for Asthma guidelines; for
COPD, BODE index score 0–2) in the intervention and control groups. The results of the COPD trial
are forthcoming this journal (BJGP Open 2019; in press) and those of the asthma trial are to be sub-
mitted for publication; in brief, the interventions were found effective in achieving disease control
Box 1. Logic model of an integrated intervention
Intervention inputs
Intervention process
and actions
Intended
Process change Outputs Health outcomes
. Case management
desk-guide & coun-
selling tool
. Training of doctors
and allied staff (on full
care package)
. Supplement drugs
and supplies (for
example, peak flow
meter)
. Recording formsa
. Screen and
diagnosea
. Prescribe and/or
dispense asthma
and/or COPD
drugs
. Counsel on lung
condition; also
smoking cessation
(if applicable)
. Follow up care,
including retrieval
Providers practise programme
protocols to:
. screen, diagnose, treat, coun-
sel, follow up, and report as
per programme protocol
Patients:
. attend follow-up visits
. adhere to treatment
. cease smoking (if applicable)
Patient are:
. screened and
diagnosed as per
programme
protocol
. prescribed and/or
dispensed correct
drug and dose
. counselled for
smoking
cessation
. followed-up and
treated for con-
tinued care
Asthma control and
BODE index change in
COPD patients
aThese inputs and practices for screening, diagnosis, and recording were the same in intervention and control arms to ensure comparing ‘like with like’ asthma and
COPD patients.
BODE index = Body-mass index, airflow Obstruction, Dyspnea, and Exercise index. COPD = chronic obstructive pulmonary disease.
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among registered COPD and asthma patients (see Box 3 for an outline of the intervention and con-
trol care).
The quantitative data of all COPD (n = 313) and asthma (n = 451) patients registered at 30 partic-
ipating facilities were analysed. To interview the care providers and patients, two districts were ran-
domly selected (Mandi Bahauddin and Kasur); and one rural health centre and one sub-district
hospital were randomly selected in each of the two districts. An equal number of rural health centres
to sub-district hospitals were purposively selected to get a balanced representation of primary and
secondary level facilities. At each of the selected facilities, one doctor (total n = 4) and one allied
staff member (total n = 4)with experience of the intervention were interviewed. In addition, one
male and one female patient with COPD (total male COPD n = 4; total female COPD n = 4), and
one male and one female patient with asthma (total male asthma n = 4; total female asthma n = 4)
was randomly selected from registered patients, invited, and interviewed at the respective health
facility (see Figure 1 for sampling for interviews).
After the authors’ experience in other similar studies,14,15 Skype call technology was used by a
qualified female researcher to conduct staff and patient interviews, during April–July 2016, at
respective facilities. After consent, the interviews were conducted in the national language (Urdu)
and were audio-recorded. Each interview, lasting for about 30 minutes, was conducted in a segre-
gated space and the interviewee was assured that their data would be kept confidential and anony-
mous. A research assistant remained available to assist interviewees with the Skype technology.
Three responders were re-contacted by telephone, to elaborate on their initial comments or on
responses that were not adequately understood.
The researcher who collected data then listened to the recorded Skype call and transcribed the
data. Another researcher then checked the transcripts while listening to the recording. The tran-
scripts were anonymised and the identification keys were kept separate from the data. The coding
frame was generated by, firstly, treating the three task categories as a priori overarching themes,
and, secondly, two researchers reviewing the transcripts to explore emergent codes and sub-
themes. The research team applied the analytical framework to the transcribed data, and responses
Box 2. Selected care tasks and key indicators
Care task
Key indicators
Quantitative Qualitative
Identification and
diagnosis of cases
1. Number of asthma and COPD patients registered (of overall outpatient
attendance)
2. Number and percentage of asthma and COPD patients receiving PEFR and/or
spirometry; and findings thereof (at baseline)
Patient’s and provider’s experiences of (also
practice deviations and reasons for):
. identifying symptoms
. conducting clinical examination and
diagnosis
Treatment and
prevention
3. Number and percentage of asthma and COPD patients prescribed inhalers (as
per guidelines) and/or other treatment to relieve and/or prevent airway
obstruction
4. Smoking cessation rate (comparing baseline and endline status)
Patient’s and provider’s experiences of (also
practice deviations and reasons for):
. prescribing, as per guide
. dispensing inhalers (drugs)
. counselling patient (tool-assisted) for
smoking cessation
. coping with input gaps
Patient follow-up
and adherence
5. Number and percentage of patient attrition on each follow-up visit (in first 6
months)
6. Number and percentage of patients referred for expert check-up and/or
complication and/or severe drug reaction
Patient’s and provider’s experiences of (also
practice deviations and reasons for):
. patient adherence to follow-up visits
(include retrieval)
. staff adherence to care during fol-
low-up visit
COPD = chronic obstructive pulmonary disease. PEFR = peak expiratory flow rate.
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were charted into the framework matrix.16 The framework approach is an analytic process of recog-
nising and managing qualitative data with summarisation to develop a conceptual framework.17
The data from different sources (staff and patients) were triangulated, and the key findings and
quotations were checked against the original transcripts to ensure trustworthiness and consistency.
Ongoing discussion and agreement by the research team framed the analysis process.
Results
The key findings, from quantitative and qualitative data sets, in each of the three task categories are
presented below.
Identification and diagnosis of chronic respiratory disease
At public-funded facilities, the proposed screening and diagnosis protocol (see Box 4) was found
able to diagnose <0.04% of the general outpatient attendees with chronic respiratory disease. In
light of the estimated disease prevalence of asthma (4%) and COPD (1%) in the general population,
the outpatient attendance seems to indicate relatively low utilisation of public health facilities for
chronic lung health care. Interviews with facility staff and patients indicate lower preference of
patients with chronic lung condition to seek treatment from a public facility, mainly because of gen-
eral non-availability of inhalers (or other drugs for chronic respiratory disease) at public facilities.
As per peak expiratory flow rate (PEFR) measurements, around two-thirds of male and more than
half of female (55%) patients had severe airway obstruction when first examined for the diagnosis of
asthma and COPD. The response to bronchodilators, measured by PEFR, was found to have been
used and reported for all patients to differentiate between asthma and COPD. In asthma, mean
Box 3. Intervention outline
Tasks
a. Diagnose on the basis of history and clinical examination
b. Register patient (complete chronic disease card)
1. Prescribe drugs, according to the disease condition (as per desk-guide)
Asthma
. Use short acting inhaled beta-2 agonist salbutamol (SABA) for quick relief (as required)
. Administer beclomethasone inhaler twice a day
. Change to beclomethasone + formeterol combination if symptoms remain uncontrolled
. Add montelukast or theophylline if symptoms remain uncontrolled
. Add oral steroid if symptoms remain uncontrolled
COPD
. Start with SABA or short acting muscarine antagonist (SAMA) inhaler
. Change to SABA and SAMA combination if symptoms remain uncontrolled
. Change to long acting beta-2 agonist (LABA) + steroid combination if symptoms remain uncontrolled
. Add long-acting muscarine antagonist LAMA or oral theophylline to LABA + steroid combination if symptoms remain uncontrolled
2. Counsel the patient, using a pictorial tool, for prevention and treatment adherence
3. Examine (clinical), prescribe (and dispense), and record, as per desk-guide, on each monthly follow-up visit
4. Identify and retrieve those found with a delay in their monthly follow-up visit (three-tray system to identify; and a mobile phone to communicate with
such patients)
The two tasks (a and b) were common for all asthma and COPD patients. The four tasks (1–4) differed in the intervention and control arms (as per desk-guide in the
intervention, and as per doctor routine in the control).
LABA = long acting beta-2 agonist. LAMA = long-acting muscarine antagonist. SABA =short-acting inhaled beta-2 agonist. SAMA = short-acting muscarine
antagonist.
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PEFR change with bronchodilator was found to be 100 (390–290) in males and 80 (325–245) in
females; whereas in COPD the pre-post difference was around 20 in both males and females. Review
of individual patient records showed a reasonable level of concurrence between PEFR results and
clinical diagnosis (decision). Interviews with the facility staff and registered patients indicate PEFR
testing to be feasible for staff, subject to availability of supplies, and acceptable to patients.
As per spirometry, FEV1% (forced expiratory lung volume in 1 second as a percent of the pre-
dicted amount from a person of similar characteristics) done within 2 weeks of patient diagnosis and
registration, around one-third of male (36%), and one-fifth of female (21%) patients had severe air-
way obstruction. Interviews with the facility and project staff indicated difficulty of offering ’on the
spot’ spirometry at the time of diagnosis and patient registration at primary and secondary level
public facilities, mainly for technical and logistical reasons:
’We lack equipment and skills for administering spirometry [on the spot]; and sending patients
to the district hospital [for spirometry] was not always possible.’ (Doctor, Sub-District Hospital,
Mandi Bahauddin)
The spirometry could only be managed by adding an additional input, for example, a qualified
person periodically visiting and conducting spirometry at the respective facilities. The spirometry
coverage indicates that most patients were able to pay an extra visit to the facility on a given date
and time to receive their spirometry free of charge.
As no other symptoms or signs (such as breathing rate, breathlessness, wheeze, difficulty talking)
were required to be recorded in the chronic disease card, it was not possible to comment on clinical
practices related to these symptoms. However, most patients mentioned auscultation as part of their
clinical examination.
The core demographic data (age, sex); contact details (address, phone number); and clinical
parameters (weight, height) were found to have been examined and recorded in all patients
Figure 1. Sampling for interviews COPD = chronic obstructive pulmonary disease. RHC = rural health centre. THQ = Tehsil headquarters.
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registered with a chronic lung condition. The data shows that around two-thirds (n = 479, 63%) of
the registered chronic lung condition cases were in male patients, and two-thirds (n = 316, 66%) of
the male patients were aged >45 years. Interviews with facility and project staff revealed that main-
taining a patient’s chronic disease card is manageable for the regular allied staff at public facilities.
However, the facility staff did require supervisory support from the district and/or project staff.
Treatment and prevention of chronic respiratory diseases
COPD prescriptions at the time of registration showed that, among 159 intervention arm patients,
96 (60%) were prescribed salbutamol, 49 (31%) were prescribed SAMA, and 14 (9%) were prescribed
both drugs. Among 154 control arm patients, 133 (86%) were prescribed salbutamol, 18 (12%) were
prescribed SAMA, and 3 (2%) were prescribed both drugs. Antibiotics were included in 29 (18%) of
intervention arm prescriptions, and 8 (5%) of the control arm prescriptions. Glucocorticosteroid and
leukotriene modifier were also included, respectively, in 3 (2%) and 8 (5%) of the intervention arm
prescriptions, and 16 (10%) and 32 (21%) of the control arm prescriptions.
Asthma prescription, at the time of registration, showed that among 226 intervention arm
patients, 52 (23%) were prescribed salbutamol alone, 72 (32%) were prescribed glucocorticosteroid
inhaler alone, and 102 (45%) were prescribed both drugs. Among 225 control arm patients, 115
(51%) were prescribed salbutamol alone, 54 (24%) were prescribed glucocorticosteroid inhaler alone,
and 56 (25%) were prescribed both drugs. Leukotriene modifier tablets were included in 23 (10%) of
intervention arm prescriptions, and 47 (21%) of the control arm prescriptions. Antibiotics were
included in 21 (9%) of intervention arm prescriptions, and 18 (8%) of the control arm prescriptions.
Interviews with facility staff revealed that none of the inhalers could be arranged through district
public budget, because of its non-inclusion in the list of essential drugs for the respective facilities:
Box 4. An outline of screening and diagnosis protocols for asthma and COPD (extracted from case management desk-guide)
Asthma COPD
Screening Asthma is indicated, if:
. younger patient (though can be an older adult)
. patient and/or family has history of asthma, allergic rhinitis (hay
fever), or eczema
. patient complains of:
 recurrent episodes of dry cough and/or difficulty breathing,
more so at night or in the morning
 worsening with exercise, cold, dust, seasonal allergens, or drugs
COPD is indicated, if:
. middle-aged or older adult who smokes or used to
smoke
. patient has a history of recurrent chest infection
. patient complains of:
 progressive persistent shortness of breath (rather than
episodic)
 cough (productive and persistent)
 exercise worsening the symptoms.
Assess for asthma or COPD diagnosis, if one or more of the above indications.
Diagnosis Diagnose asthma, if patient has history of 1 asthma indications, and
during an exacerbation has:
. wheeze (widespread and more on expiration)
. on investigation (may be normal):
 PEFR during an exacerbation <80% which improves with
bronchodilator
 other supporting/ indicative investigations:
& blood CP (eosinophil >5%, though also in bronchitis and
COPD)
& chest X-rays (not usually indicated; may be normal, may be
hyperinflation)
Diagnose COPD, if patient has history of 1 COPD indications,
and has:
. wheeze – widespread and more on expiration
. on investigation:
 PEFR during an exacerbation <80%, with minor or no
change with bronchodilator
 other supporting/ indicative investigations:
& blood CP (to check for anemia and polycythemia, if
required)
& chest X-rays (vertical heart, hyperinflated lungs, low-
set diaphragm)
COPD = chronic obstructive pulmonary disease. Blood CP = blood complete picture. PEFR = peak expiratory flow rate.
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’We cannot purchase inhalers from the facility budget, unless these get included in our list of
essential drugs.’ (Doctor, Sub-District Hospital, Kasur)
The staff at intervention facilities reported that salbutamol, glucocorticosteroid, and SAMA
inhalers were provided through project inputs for free of charge dispensing, whereas leukotriene
modifier tablets were prescribed for the patient to buy themselves. No staff member or patient
reported any complaint regarding quality of the drugs procured and distributed through the respec-
tive programme support.
The facility staff indicated general patient expectation of getting free drugs at a public facility.
The non-provision of free drugs (inhalers) seems to add to the risk of patient non-adherence, espe-
cially if they are less able to buy drugs. The staff perceives that non-provision of inhalers at public
facilities need be addressed before possible scaling of chronic lung healthcare:
’Free provision of inhalers [from the health facility] made it possible for me to take treatment
without interruption.’ (Patient, Rural Health Centre, Mandi Bahauddin)
At the time of registration, around one-third of male patients (n = 174, 36%), and only 13 (5%)
female patients were reported to smoke. At the time of outcome measurement after 6 months of
registration, n = 92/174 (53%) male patients and n = 1/13 (7%) female patients were reported to
have continued smoking. The reported average duration of the first smoking cessation counselling
session was about 15 minutes, whereas duration of subsequent counselling sessions was generally
<5 minutes. Staff and patients reported that members of staff prioritised smoking cessation counsel-
ling for patients with chronic lung conditions, and neither faced logistical or social constraint to the
patient being counseled:
“Patients with chronic lung conditions are generally more receptive to our ’quit smoking’
advice.” (Paramedic, Sub-District Hospital, Kasur)
Patient follow-up and adherence
As shown in Figure 2, the adherence rate for the first five follow-up visits in COPD and asthma
patients was 64% (n = 506/795) and 60% (n = 672/1130) respectively in the intervention arm, com-
pared to 32% (n = 246/770) and 30% (n = 330/1125) respectively in the control arm. Patient non-
adherence to follow-up visits during the first 6 months seems to be a major treatment challenge in
both the intervention and control arms. However, comparison of the two arms indicates relatively
lower and slower attrition among those exposed to the intervention. This difference seems more
marked for the second and third follow-up visits. The three-tray system was reported mostly to be in
place for managing patient cards at 15 intervention health facilities. Interviews with staff and patients
indicated that free drugs were an incentive for patients to attend the facility, and that enhanced
patient retrieval was helpful for adherence to follow-up visits. The allied staff reported no difficulties
with regards calling to remind male and female patients about their follow-up visits:
’I generally use the mobile number of husbands to remind women [patients] about their due
follow-up visits.’ (Paramedic, Rural Health Centre, Kasur)
The record review of 576 (intervention COPD and asthma combined) and 1178 (control COPD
and asthma combined) follow-up visits, showed 98% compliance (n = 1719/1754) to the assessment
and recording of PEFR at each follow-up visit. The staff did not report any challenge to examining
the patient on their follow-up visits. However, the staff did report the importance of uninterrupted
supplies (such as disposable mouth pieces) and equipment maintenance (for example, of the peak
flow meter) for their compliance with the patient examination requirement. Some patients seem to
face social challenges to accessing free lung care (including drugs) at public funded facilities:
’Some male patients find it difficult to come every month, because of other engagements
during the hospital [outpatient] timing.’ (Paramedic, Sub-District Hospital, Mandi Bhauddin)
The referral of patients with severe lung conditions was reported to have been practised at public
facilities, but no records of this were found to have been maintained. The facility staff indicated that
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patient families appraise the referral care suggestion, and select the source and the timing of spe-
cialist care (when advised) in light of the advice and their own circumstances.
Discussion
Summary
The two cluster randomised trials have shown the integrated care at primary and secondary level
health facilities to be effective in controlling two chronic lung conditions (COPD and asthma). This
process evaluation study showed that the delivery of integrated chronic lung care, as per pro-
gramme protocols, is feasible for staff and patients in routine PHC settings.
Strengths and limitations
Using routine clinical records as the main source of quantitative analysis made the data collection
efficient (for example, causing minimal added cost), but some variables of interest were not avail-
able, such as education level and occupation. There is a lack of literature evaluating the use of Skype
technology to interview health workers and patients in applied health research, with participant dis-
comfort and technical failure possible drawbacks. The authors’ experience, however, was broadly
positive, and use of Skype technology enabled the more efficient use of the expert interviewer’s
time.
Comparison with existing literature
The rate of reported smoking cessation by male patients with chronic lung condition (47%), was
close to the cessation rate previously achieved (around 40%) among patients with suspected
Figure 2. Asthma and COPD patient attrition in intervention and control arms COPD = chronic obstructive pulmonary disease.
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tuberculosis in Pakistan.8 The intervention was found to have improved the attendance for follow-up
visits. However, high attrition (even in intervention arm) does indicate the need for improving treat-
ment adherence through implementation research on various potential options,18 such as reducing
the frequency of follow-up visits (unless clinically indicated),14 extending the timing of hospital out-
patient, adding a treatment supporter,19 and developing public–private partnership for expanded
coverage and continued care.20
To assess the degree of airway obstruction at the time of diagnosis or registration, healthcare
staff performed PEFR examination on the spot, and spirometry was administered, as a research
related measurement, within 2 weeks of patient diagnosis. In this study, spirometry (as compared to
PEFR) identified a lower number (proportion) of severe airway obstruction among registered
patients. This is different from other reported experience,21 which found that spirometry to be a
more sensitive measure of airway obstruction severity. As spirometry (for logistic reasons) was
administered within 2 weeks of treatment initiation, spirometry identifying lower number (propor-
tion) of severe airway obstructions in this study seems plausible.
This study identified both equipment and staff skill challenges to offering on the spot spirometry
at primary and secondary level health facilities in a developing country setting. Experiences in two
developed countries (UK22 and Italy)23 found offering spirometry without specialist input to be feasi-
ble, but managing providers’ protocol violation and patients’ inability to participate or perform did
pose challenges. Furthermore, the UK study found spirometry to add to the quality of diagnosis at
general practice level; in Italy the evidence for the same was inconclusive. The present study’s find-
ings do not suggest that decentralising spirometry to the PHC level would be feasible.
Availability of drugs is considered important for patients to attend their facility and adhere to
treatment.24 At the time when the trial was implemented, inhalers (the main drug used to treat
chronic lung conditions) were not included in the list of essential drugs for PHC facilities. Inhalers
were included as part of the intervention arm package to generate experience-based learning for
scaled implementation. Education on how to administer inhalers, as an important care
component,25 was also made a part of patient counselling at registration and during follow-up visits.
About 20% of asthma and COPD patients being prescribed leukotriene modifier tablets seems in
line with the generally reported26 tendency of physicians to overprescribe, even when the drug is
not made available for free dispensing. Another study14 on non-communicable disease care in Paki-
stan reported the prescription of drugs to be a blend of doctor and patient preferences, with some
doctors prescribing high-cost pharmaceutical products because of fancy packaging and active
marketing.
Implications for research and practice
In light of effectiveness (as shown in the two trial results) and feasibility (as shown by the process
evaluation study), the integrated chronic lung care intervention is being scaled in the province, and
inhalers have also been added to the list of essential drugs for PHC facilities. However, implementa-
tion research may be considered for enhanced adherence to follow-up care.
This study shows that integrating COPD and asthma care into routine healthcare at primary and
secondary level public facilities is feasible and acceptable. Integrated COPD and asthma care can
lead to improved assessment, diagnosis, prescription practices, and adherence to follow-up appoint-
ments in a low-income country setting, with promising results. The evidence from the trial and the
process evaluation study support the recommendation for scaled implementation in developing
country settings.
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